Results for tag: "Ixazomib"

Ixazomib is an oral proteasome inhibitor used in the treatment of multiple myeloma, a type of cancer that affects the plasma cells in the bone marrow. It is the first and only oral proteasome inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of multiple myeloma. Ixazomib is used in combination with lenalidomide and dexamethasone, and is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. It works by blocking the activity of proteasomes, which are proteins that break down other proteins in the body. This helps to slow down the growth of cancer cells. Ixazomib is part of a growing market of oncology drugs, which are used to treat a variety of cancers. These drugs are designed to target specific cancer cells, while minimizing the damage to healthy cells. They are often used in combination with other treatments, such as chemotherapy and radiation therapy. Some companies in the Ixazomib market include Takeda Pharmaceuticals, Bristol-Myers Squibb, and Celgene. Show Less Read more